No abstract

Introduction: Since photobiomodulation therapy (PBMT) favors in vitro mesenchymal stem cell (MSC) preconditioning before MSC transplantation, increasing the proliferation of these cells without molecular injuries by conserving their characteristics, in the present in vitro study we analyzed the effect of PBMT on the proliferation and osteogenic differentiation of human umbilical cord mesenchymal stem cells (hUCMSCs). Methods: Irradiation with an InGaAIP Laser (660 nm, 10 mW, 2.5 J/cm 2 , 0.08 cm 2 spot size, and 10 s) was carried out. The cells were divided into four groups: CONTROL [cells grown in Dulbecco's Modified Eagle Medium (DMEM)], OSTEO (cells grown in an osteogenic medium); PBMT (cells grown in DMEM+PBMT), and OSTEO+PBMT (cells grown in an osteogenic medium plus PBMT). The cell proliferation curve was obtained over periods of 24, 48 and 72 hours using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Osteogenic differentiation was analyzed by the formation of calcium nodules over periods of 7, 14 and 21 days. Morphometric analysis was performed to quantify the total area of nodular calcification. Results: The highest cell proliferation and cell differentiation occurred in the OSTEO+PBMT group, followed by the PBMT, OSTEO and CONTROL groups respectively, at the observed times (P < 0.05). Conclusion:PBMT enhanced the osteogenic proliferation and the differentiation of hUCMSCs during the periods tested, without causing damage to the cells and preserving their specific characteristics, a fact that may represent an innovative pretreatment in the application of stem cells.

Lectins (carbohydrate-binding proteins) are able to distinguish different patterns of glycosylation on cell surfaces. This study investigated the effects of lectins from Alpinia purpurata inflorescence (ApuL) and Schinus terebinthifolia leaf (SteLL) on the viability of human leukemia cells (K562, chronic myeloid leukemia; JURKAT, acute lymphoblastic leukemia) and mesenchymal stem cells (MSCs) from human umbilical cords. In addition, possible immunomodulatory effects of ApuL and SteLL on MSCs were assessed by determining cytokine levels in cultures. ApuL reduced the viability of JURKAT cells (IC50: 12.5 μg/mL), inducing both apoptosis and necrosis. For K562 cells, ApuL at 50 µg/mL caused a decrease in viability, but of only 8.8%. Conversely, SteLL exerted a cytotoxic effect on K562 (IC50: 6.0 μg/mL), inducing apoptosis, while it was not cytotoxic to JURKAT. ApuL and SteLL (0.19–100 μg/mL) did not decrease MSCs viability. Treatment with ApuL strongly suppressed (99.5% reduction) the release of IL-6 by MSCs. SteLL also reduced the levels of this cytokine in culture supernatant. In conclusion, ApuL and SteLL showed potential to reduce the viability of leukemia cells, as well as immunomodulatory effect on MSCs without being toxic to them. These biological properties can be explored biomedically and biotechnologically in the future.

No abstract

No abstract